With its increasing prevalence, diabetes mellitus (DM) has been a serious public health issue in contemporary society, which has already affected more than 537 million adults worldwide in 2021 and approximately 643 million by 2030.

Genetic and environmental predisposing factors contribute to the etiology of the disease, although their interaction is not sufficiently understood to allow for preventive action. Oct 1, 2001 · At first sight, it could be thought that gene therapy is not applicable to type 1 diabetes because there is no single faulty gene that needs to be corrected.

New approaches.

Efforts to prevent T1D have focused on modulating immune responses and supporting beta cell health; however, heterogeneity in disease progression and responses to therapies have made these efforts difficult to.

However, molecular manipulation of transplanted islets or cells to shield them from immune attack to avoid allorejection, recurrence of disease, or both is certainly an attractive proposition. Part 3 The thyroid. .

Nonetheless, some patients cannot maintain glycemic control.

5. Management of T1DM is challenging and complicated especially with conventional medications. (A, B) Monoclonal antibodies (mAb) treatments can be broadly divided into two categories: depleting mAb or nondepleting (ND)/neutralizing mAb.

. 5.

, 2008.

Gene Therapy; Wounds and Healing.

Contents. .

. Gene- and cell-based therapeutics for type I diabetes mellitus.

It is not unusual for patients with type 1 diabetes to present with diabetic ketoacidosis (DKA).
Feb 18, 2021 · This review will discuss strategies applied and advancements made in mAb therapies for T1D prevention and treatment.

Gene therapy in diabetes mellitus.


Apr 1, 2021 · Type 1 diabetes affects millions of people globally and requires careful management to avoid serious long-term complications, including heart and kidney disease, stroke, and loss of sight. . This review, in addition to updating the growing list of type 1 diabetes-relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with which.

. . This review primarily focuses on the current status and the future. . . .


. Part 2 Pituitary and hypothalamic diseases.


Gene therapy, an emerging treatment for cancers.

Over the years, prevalence of diabetes has increased globally and it is classified as one of the leading.


Part 1 Principles of international endocrine practice.